Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

NCT05322330 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: Selinexor
DRUG: Flu
DRUG: CTX
DRUG: CAR-T

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]